What happened
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) entered an asset purchase agreement on October 8, 2026, to sell a Rare Pediatric Disease Priority Review Voucher.
The U.S. Food and Drug Administration awarded the voucher on September 17, 2026, after approving FAYUVI, also known as UX111.
The buyer agreed to pay $203 million in cash when the transaction closes.
The deal still depends on customary closing conditions, including the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.
Key numbers
| Metric | Latest | Change | Source |
|---|---|---|---|
| Cash payment upon closing | $203 million | SEC 8-K | |
| FDA award date | September 17, 2026 | SEC 8-K | |
| Asset purchase agreement date | October 8, 2026 | SEC 8-K |
Read more: Ultragenyx Pharmaceutical (RARE) stock analysis and investment case
Why it matters
OptimistFi's case is that Ultragenyx can keep turning rare- and ultra-rare-disease approvals into revenue fast enough to outrun a still-large cash burn and balance-sheet burden.
This filing supports that view by turning a September 17 FDA award into a $203 million cash sale agreement on October 8.
The PRV came after FDA approved FAYUVI, so the filing links a recent regulatory win to a cash value.
The buyer agreed to pay in cash at closing, which gives the voucher a clear price if the deal gets through the last steps.
The agreement is still subject to customary closing conditions, including the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.
That keeps the payment contingent, but it also shows a direct path for Ultragenyx to monetize the voucher if the transaction closes.
Browse: stock research on every company OptimistFi covers
What's next
The next dated step is closing after the applicable Hart-Scott-Rodino waiting period expires or is terminated.
If closing happens, Ultragenyx receives $203 million in cash under the agreement.
If the waiting period does not end or the deal otherwise does not close, the payment stays contingent.
Investors can watch that regulatory step as the main test of whether the voucher turns into cash on the stated terms.
More from OptimistFi
- RARE stock: the Ultragenyx Pharmaceutical thesis, its status and the next test to watch
- Stock research on every company OptimistFi covers
- Latest stock research and investment-case updates
- OptimistFi: evidence-first equity research
Sources
- SEC 8-K — Ultragenyx Pharmaceutical Inc. entered into an asset purchase agreement to sell a Rare Pediatric Disease Priority Review Voucher for $203 million in cash, subject to closing conditions.
Read the full OptimistFi thesis on Ultragenyx Pharmaceutical Inc.: https://optimistfi.com/stocks/RARE
See what would break the Ultragenyx Pharmaceutical Inc. thesis and track it live on the OptimistFi Thesis-Break Engine.
Browse every company OptimistFi covers at optimistfi.com/stocks, or read the latest evidence-first research.
The full Ultragenyx Pharmaceutical Inc. investment case, its status and the next test to watch live on the Ultragenyx Pharmaceutical Inc. thesis page.
Originally published on OptimistFi, evidence-first equity research. More at optimistfi.com.
